Inventor · disambiguated record
Mark Trautwein
Also filed as: TRAUTWEIN MARK
11 granted patents·11 pending applications·43 citations·filing 2010–2024
87Inventor score
Files withBAYER AG9Bayer Pharma AG5BAYER IP GMBH2DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS2OTTO CHRISTIANE2
Top patents by PatentIndex Score
22 records- 0189US11071788B2Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodiesBayer Pharma AG·Filed 2016·Granted Jul 27, 2021·6 cites·32 claims
- 0285US10584167B2Anti-CEACAM6 antibodies and uses thereofBayer Pharma AG·Filed 2016·Granted Mar 10, 2020·4 cites·16 claims
- 0385US9382305B2Relaxin fusion polypeptides and uses thereofWILMEN ANDREAS·Filed 2012·Granted Jul 5, 2016·20 cites·17 claims
- 0480US9777063B2Neutralizing prolactin receptor antibody Mat3 and its therapeutic useBAYER IP GMBH·Filed 2016·Granted Oct 3, 2017·3 cites·4 claims
- 0579US11866495B2Anti-CEACAM6 antibodies and uses thereofDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2020·Granted Jan 9, 2024·1 cites·20 claims
- 0679US2024376218A1Ccr8 antibodies for therapeutic applicationsBAYER AG·Filed 2024·Application pending·0 cites
- 0779US2024400700A1Ccr8 antibodies for therapeutic applicationsBAYER AG·Filed 2024·Application pending·0 cites
- 0876US9649374B2Neutralizing prolactin receptor antibodies and their therapeutic useOTTO CHRISTIANE·Filed 2010·Granted May 16, 2017·5 cites·5 claims
- 0972US12065497B2Methods of treatment using CCR8 antibodiesBAYER AG·Filed 2022·Granted Aug 20, 2024·0 cites·17 claims
- 1068US9241989B2Neutralizing prolactin receptor antibodies and their therapeutic useOTTO CHRISTIANE·Filed 2010·Granted Jan 26, 2016·2 cites·16 claims
- 1166US9353186B2Neutralizing prolactin receptor antibody Mat3 and its therapeutic useFREIBERG CHRISTOPH·Filed 2012·Granted May 31, 2016·2 cites·14 claims
- 1261US11773164B2Anti-CEACAM6 antibodies and uses thereofBayer Pharma AG·Filed 2020·Granted Oct 3, 2023·0 cites·20 claims
- 1361US2024124572A1INHIBITORS OF IL-11 OR IL-11Ra FOR USE IN THE TREATMENT OF ABNORMAL UTERINE BLEEDINGBAYER AG·Filed 2022·Application pending·0 cites
- 1461US2024317847A1INHIBITORS OF IL-11 OR IL-11Ra FOR USE IN THE TREATMENT OF ABNORMAL UTERINE BLEEDINGBAYER AG·Filed 2022·Application pending·0 cites
- 1556US2024108766A1Lrrc15 antibodies and conjugates thereofBAYER AG·Filed 2022·Application pending·0 cites
- 1655US2025326851A1Medical use of ccr8 antibodies and dosing scheduleBAYER AG·Filed 2023·Application pending·0 cites
- 1754US2024368280A1Anti-cecam6 antibodies with reduced side-effectsDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2022·Application pending·0 cites
- 1850US12221479B2Pharmaceutical combination of anti CEACAM6 and TIM3 antibodiesBAYER AG·Filed 2019·Granted Feb 11, 2025·0 cites·11 claims
- 1947US2014322220A1Anti-FGFR2 Antibodies and Uses ThereofBAYER IP GMBH·Filed 2012·Application pending·0 cites
- 2045US2022010017A1Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancerBAYER AG·Filed 2019·Application pending·0 cites
- 2143US2016009776A1Pdgfrbeta-fc fusion proteins and uses thereofBayer Pharma AG·Filed 2014·Application pending·0 cites
- 2237US2019298865A1Radio-pharmaceutical complexesBayer Pharma AG·Filed 2017·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →